- Alexandria Real Estate reported their 1Q AFFO/share as $2.35, which is higher than the estimated $2.32 and the previous year’s $2.19.
- The company’s revenue reached $769.1 million, a 9.7% increase from the previous year. This surpassed the estimated revenue of $765.1 million.
- Earnings per share (EPS) was reported as 97c, significantly higher than both the estimate of 84c and last year’s 44c.
- Among financial analysts, there were 13 buy recommendations, 1 hold, and no sell recommendations for Alexandria Real Estate’s stocks.
A look at Alexandria Real Estate Equities Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Alexandria Real Estate Equities appears to have a positive long-term outlook. The company has strong scores in both value and dividend categories, indicating solid potential for growth and income generation for investors. While growth, resilience, and momentum scores are not as high as value and dividend, they still suggest a stable and promising future for the company.
Alexandria Real Estate Equities, Inc. is a company that focuses on acquiring, managing, expanding, and developing office and laboratory space properties. With a diverse portfolio of properties leased to various industries such as pharmaceutical, biotechnology, and research institutions, Alexandria Real Estate Equities operates in key regions including California, suburban Washington D.C., New England, the Mideast, and Southeast. The company’s focus on properties in high-demand sectors and strategic locations positions it well for long-term success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
